http://hl7.org/fhir/uv/ebm/Evidence/6512
type: Evidence
node role: treeRoot
id:
  v: 6512
meta:
  version id:
    v: 3
  last updated:
    v: 2026-08-06T09:26:00.989Z
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Evidence 6512 version: 3; Last updated: 2026-08-06 09:26:00+0000 ArtifactPublicationStatus: Active url: https://fevir.net/resources/Evidence/6512 identifier: FEvIR Object Identifier/6512 name: OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001 title: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint citeAs: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json. status: Active date: 2021-07-19 21:20:42+0000 author: Brian S. Alper: publisher: Computable Publishing LLC contact: support@computablepublishing.com copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ description: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide. variableDefinition description: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. variableRole: Population observed: Group NCT04401202_Enrollment_Group intended: NCT04401202 Eligibility Criteria variableDefinition description: Nigella Sativa Oil (NSO) variableRole: Exposure observed: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care variableDefinition description: Control variableRole: Exposure observed: standard of care medications alone variableDefinition description: proportion of patients recovered (free of sym…
extension:
  url:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
    l: artifact-publication-status
  value: CodeableConcept
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
        l: cited-artifact-status-type
      code:
        v: active
      display:
        v: Active
url:
  v: https://fevir.net/resources/Evidence/6512
  l: https://fevir.net/resources/Evidence/6512
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: ACSN
      display:
        v: Accession ID
    text:
      v: FEvIR Object Identifier
  system:
    v: https://fevir.net/FOI
    l: FOI
  value:
    v: 6512
  assigner:
    display:
      v: Computable Publishing LLC
name:
  v: OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001
title:
  v: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
cite as:
  v: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json.
status:
  v: active
date:
  v: 2021-07-19T21:20:42.620Z
author:
  name:
    v: Brian S. Alper
publisher:
  v: Computable Publishing LLC
contact:
  telecom:
    system:
      v: email
copyright:
  v: https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
  v: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
variable definition:
  description:
    v: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
  variable role:
    v: population
  observed:
    l: http://hl7.org/fhir/uv/ebm/Group/5224
    reference:
      v: Group/5224
    type:
      v: Group
      l: Group
  intended:
    l: http://hl7.org/fhir/uv/ebm/Group/189713
    reference:
      v: Group/189713
    type:
      v: Group
      l: Group
    display:
      v: NCT04401202 Eligibility Criteria
variable definition:
  description:
    v: Nigella Sativa Oil (NSO)
  variable role:
    v: exposure
  observed:
    display:
      v: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care
variable definition:
  description:
    v: Control
  variable role:
    v: exposure
  observed:
    display:
      v: standard of care medications alone
variable definition:
  description:
    v: proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization
  variable role:
    v: outcome
  observed:
    l: http://hl7.org/fhir/uv/ebm/EvidenceVariable/5269
    reference:
      v: EvidenceVariable/5269
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization
statistic:
  description:
    v: There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).
  number affected:
    v: 58
  sample size:
    number of studies:
      v: 1
    known data count:
      v: 94
  attribute estimate:
    quantity:
      value:
        v: 0.001

v: C44185

v: P-value